



**UNIVERSITY OF LEEDS**

This is a repository copy of *New and emerging therapies for Clostridium difficile infection*.

White Rose Research Online URL for this paper:

<http://eprints.whiterose.ac.uk/134868/>

Version: Accepted Version

---

**Article:**

Martin, J and Wilcox, M [orcid.org/0000-0002-4565-2868](https://orcid.org/0000-0002-4565-2868) (2016) New and emerging therapies for Clostridium difficile infection. *Current Opinion in Infectious Diseases*, 29 (6). pp. 546-554. ISSN 0951-7375

<https://doi.org/10.1097/QCO.0000000000000320>

---

© 2016 Wolters Kluwer Health, Inc. This is an author produced version of a paper published in *Current Opinion in Infectious Diseases*. Uploaded in accordance with the publisher's self-archiving policy.

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

## **New and emerging therapies for *Clostridium difficile* infection**

### **Dr Jessica Martin**

Academic Clinical Fellow, Leeds Teaching Hospitals NHS Trust/University of Leeds.

Microbiology, Old Medical School, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX, UK.

### **Professor Mark Wilcox**

Consultant / Head of Microbiology, Leeds Teaching Hospitals NHS Trust;

Professor of Medical Microbiology & Sir Edward Brotherton Chair of Bacteriology, University of Leeds; Lead on *C. difficile* infection, Public Health England.

Corresponding author:

Professor Mark Wilcox

Microbiology,

Old Medical School,

Leeds General Infirmary,

Leeds LS1 3EX,

W. Yorks., UK.

[mark.wilcox@nhs.net](mailto:mark.wilcox@nhs.net)

Tel +44 113 392 6818

Fax +44 113 392 2696

### **Keywords (3-5)**

*Antibiotics, live biotherapeutics, antibodies, vaccines*

**Abstract (max 200 words)**

*Purpose of review:* *Clostridium difficile* infection has attained high prominence given its prevalence and impacts on patients and healthcare institutions. Multiple new approaches to the prevention and treatment of CDI are undergoing clinical trials.

*Recent findings:* Bezlotoxumab is a monoclonal antibody against toxin B that has successfully completed phase three studies, demonstrating a significant reduction in recurrent CDI when given with standard of care antibiotics. Antibiotics under development include cadazolid and ridinilazole, while surotomycin has had disappointing phase 3 results. Multiple live biotherapeutics are being developed, including freeze thawed and encapsulated versions of faecal microbiota transplantation to improve the practicality of treating patients with recurrent CDI. Alternatives to faecal microbiota transplantation, that aim to improve safety, including a microbial suspension, RBX2660, and a complex spore formulation, SER-109, have progressed to phase 2 studies. A non-toxigenic *C. difficile* strain has also shown promise to prevent recurrent CDI. In addition, three *C. difficile* vaccines have progressed to phase 2/3 clinical trials.

*Summary:* The diverse approaches to treating and preventing CDI offer substantial promise that new treatment options will soon emerge, particular ones that reduce the risk of recurrences.

## Introduction

In the US, *C. difficile* infection (CDI) occurs at a rate of 150 cases per 100,000 population per year creating a significant burden to patients, relatives and healthcare providers.<sup>1</sup> In modern healthcare, sophisticated medical interventions (e.g. organ transplantation, complex surgery and cancer treatments) come at the cost of an increased infection risk. In particular, antibiotic treatment causes dysbiosis of the host gut microflora and an increased risk of CDI. Complex health needs are unlikely to diminish, and so, together with an aging population, antibiotic stewardship programmes aimed at reducing the use of 'high-risk' antibiotic prescribing should reduce, but not eliminate, the risk of CDI. Strategies to reduce healthcare exposure to *C. difficile*, such as source isolation of CDI cases and enhanced environmental cleaning, have reduced CDI rates in some regions.<sup>2</sup> However, meticulous adherence to these interventions is unlikely to remove the risk of CDI entirely due the widespread presence of *C. difficile* in healthcare settings, the environment, livestock and (occasionally) food.<sup>3-5</sup> Therefore, there is an urgent need for effective CDI prevention and treatment strategies.

Currently, three antimicrobial agents provide the mainstay of CDI therapy; vancomycin, metronidazole and fidaxomicin.<sup>6-7</sup> Several novel antimicrobial agents are in development and, if successful, may increase the range of agents available to clinicians (Table 1). In addition, studies demonstrating the efficacy of faecal microbiota transplantation (FMT) for the treatment of recurrent CDI<sup>8-9</sup> have sparked interest in CDI interventions designed to target gut dysbiosis that typically involves reduced diversity.<sup>10</sup> These therapies may be particularly helpful for recurrent CDI, which occurs in approximately a quarter of patients following primary infection. Host gut antibody-mediated immunity is also known to be important to CDI pathogenicity,<sup>11</sup> and recent interventional trials have targeted this by using either pre-emptive vaccination strategies or passive antibodies (in addition to standard therapy). This review summarises emerging preventative and therapeutic approaches for CDI, with a brief description of each strategy and its stage of development.

## Current CDI antibiotics

The usage of metronidazole and vancomycin for the treatment of CDI have been comprehensively described previously.<sup>12</sup> The most significant recent findings are from a pooled analysis of two phase III trials of tolevamer (a toxin binding polymer), which failed to demonstrate equivalence to standard treatment.<sup>13</sup> These data additionally showed that clinical success occurred significantly less often following metronidazole compared to vancomycin therapy (73% and 81%, respectively,  $p=0.02$ ).<sup>13</sup> However, metronidazole continues as first-line CDI therapy in many countries due to low acquisition

cost and the perceived risk of VRE with vancomycin.<sup>6-7</sup> Oral vancomycin is often recommended for severe or complicated CDI.<sup>6-7</sup>

Fidaxomicin was added to the CDI treatment repertoire following FDA approval in 2011.<sup>14</sup>

Fidaxomicin is an oral macrocyclic agent which inhibits RNA synthesis and demonstrates relatively little perturbation of the host microbiota<sup>15</sup> whilst achieving high faecal concentrations and reduced toxin and spore levels.<sup>16-17</sup> In two large phase III trials, fidaxomicin demonstrated non-inferiority to vancomycin and was associated with reduced CDI recurrence (15.4% after fidaxomicin vs. 25.3% after vancomycin,  $p=0.005$ ).<sup>18-19</sup> Lower cure rates using fidaxomicin (or vancomycin) were noted in BI/NAP1/ribotype 027 infections. Fidaxomicin is included in European guidelines on CDI treatment,<sup>7</sup> but usage has been limited by high drug acquisition cost. However, some studies suggest that the cost of this agent can be offset by reduced disease recurrence and shorter hospital admissions.<sup>20,21</sup> A recent before and after design study reported reduced mortality in some settings where fidaxomicin was the preferred CDI treatment agent.<sup>21</sup>

### **Novel antimicrobial therapy for CDI**

The ideal antimicrobial agent for CDI would reduce vegetative *C. difficile* cells, toxins and spores in the host gut lumen without encouraging host microbial resistance (e.g. vancomycin resistant enterococci [VRE] or multi-resistant Gram negative bacilli [MRGNB]), perturbation of the host microbiota<sup>11</sup> or systemic adverse effects. It is enormously challenging for a single agent to meet all these criteria, but a number of promising new therapies are being investigated (summarised in Table 1).

Surotomylin is an oral lipopeptide antibiotic, which was developed semi-synthetically from daptomycin.<sup>22-25</sup> A randomised multi-centre double-blind non-inferiority controlled phase 2 trial compared surotomylin with vancomycin ( $n=210$ ). This study demonstrated non-inferiority using 125 mg and 250 mg surotomylin doses when compared with oral vancomycin (92% and 87% vs. 89%, respectively).<sup>26</sup> Recurrence was lower in the surotomylin groups (28% [125mg group] and 17% [250mg group]) compared with vancomycin (36%) but the trial was too small to demonstrate significant outcome differences.<sup>27</sup> However, recent data from phase III trials (NCT01598311 and NCT01597505) comparing surotomylin with vancomycin have failed to demonstrate non-inferiority of surotomylin compared with vancomycin.<sup>28</sup> As such, it is doubtful that surotomylin will continue to be developed.

Cadazolid (Actelion) is a novel hybrid oxazolidinone-fluroquinolone antibiotic that inhibits *C. difficile* protein synthesis and, to a lesser extent, DNA synthesis, which is very poorly absorbed after oral twice daily administration, achieving high faecal concentrations but with relatively low impact on host microbiota.<sup>29-31</sup> A phase 2 double-blind, double-dummy, randomised study (n=84) showed that time to CDI symptom resolution was similar for cadazolid and vancomycin.<sup>32</sup> Cadazolid had a greater sustained response rate (primary cure without recurrence) compared with vancomycin (60%, 56%, 47% for 250mg, 500mg and 1000mg cadazolid, respectively, and 33% for vancomycin). However, this study had an unusually low response rate to vancomycin. A Phase III double-blind trial (NCT01987895) investigating non-inferiority to vancomycin in terms of clinical response and superiority in terms of sustained response is currently recruiting.

Ridinilazole (SMT19969) is a novel non-absorbable very narrow-spectrum antimicrobial<sup>33</sup> with minimal activity against host gut microbiota but good activity against selected clostridia including *C. difficile*.<sup>34-37</sup> Safety and tolerability has been demonstrated in healthy subjects and in a recently completed phase II randomised double-blind trial (CoDIFy).<sup>38,39</sup> CoDIFy was designed as a non-inferiority study and compared oral ridinilazole 200mg bd with oral vancomycin 125mg qds, both for 10 days; sustained clinical response rates were 67% and 42%, respectively (n=69 mITT population). Recurrence occurred in 14% of the ridinilazole group compared with 35% of the vancomycin group; this difference meant that ridinilazole achieved a sustained response rate of 66.7% versus 42.4% for vancomycin, which met pre-set statistical superiority criteria.<sup>39</sup>

### ***C. difficile* infection prophylaxis**

Ribaxamase (SYN-004, synthetic biologics) is a recombinant beta-lactamase which has been formulated as an oral accompaniment to beta-lactam antibiotics.<sup>40-41</sup> This agent degrades unmetabolised antibiotic in the host intestine in order to protect the gut microbiota from dysbiosis and is well tolerated.<sup>42</sup> Animal studies have demonstrated safety without interference with the systemic pharmacokinetics of ceftriaxone.<sup>41</sup> A phase 2 double-blind placebo-controlled study is ongoing and will examine safety and whether ribaxamase can reduce CDI risk.

Another novel approach to CDI prophylaxis is DAV132 (DaVolterra), which is an activated charcoal based product in an enteric coated pill.<sup>43</sup> This adsorbent product irreversibly captures antibiotics in the intestine whilst hopefully avoiding interruption of antibiotic absorption. DAV132 has been examined in a proof-of-concept study involving 18 healthy subjects. *In vitro* human gut model and *in vivo* hamster models also have positive findings but clinical efficacy data are awaited.<sup>43</sup>

### **Active *C. difficile* immunisation**

Vaccination to boost host antibody-mediated immunity is a promising strategy to reduce CDI. A previous model of CDI vaccination demonstrated cost-effectiveness even with wide-ranging risks of CDI and varied vaccine efficacies and costs.<sup>44</sup> A CDI vaccine is therefore an appealing goal, with the potential for substantial clinical impact in healthcare institutions across the world.

#### *Host immunity to CDI*

*C. difficile* virulence is largely governed by two protein exotoxins, toxin A (TcdA) and toxin B (TcdB). The host immune response to these toxins likely influences the likelihood of disease, clinical severity and outcome of CDI.<sup>10</sup> A previous prospective study in 271 patients demonstrated higher serum IgG levels to *C. difficile* TcdA in patients with asymptomatic colonisation compared with those with CDI.<sup>45</sup> Furthermore, recurrent CDI has been associated with poor IgG and IgM responses supporting the hypothesis that reduced immune response leads to poor outcomes.<sup>46</sup>

Serum toxin-neutralising antibody can be measured to assess *C. difficile* vaccine efficacy. A good antibody response to TcdA seems most important, but recent evidence suggests that an effective vaccine requires neutralisation to both TcdA and TcdB.<sup>47</sup> Other antigens may also be important; antibodies to surface proteins are greater in *C. difficile* colonised versus infected patients.<sup>48</sup> Ideally, *C. difficile* vaccines could include targets that reduce primary colonisation as well as toxin neutralisation. A key issue for trials is which subjects will best benefit from vaccination.

#### *Phase II/III C. difficile vaccines*

Three vaccines that use *C. difficile* toxin targets have reached at least phase II trials. The most advanced is a formalin-inactivated toxoid-based vaccine developed by Sanofi Pasteur.<sup>49</sup> Six phase I trials have demonstrated it to be safe and well tolerated. Seroconversion to TcdA was stronger than TcdB (but took up to 70 days) and response was less common in elderly subjects (>65 years). Three doses were required to achieve an adequate neutralising-antibody response.<sup>49-50</sup> A randomised placebo-controlled two-stage phase II trial compared low versus high dose vaccine, both with and without an aluminium hydroxide (AlOH) adjuvant (n=455), and assessed schedules of administration (n=206). A 100 µg dose (with AlOH) had the best immunogenic profile and was chosen for future trials.<sup>51</sup> A phase III trial to assess the safety and efficacy of this vaccine in preventing primary CDI in at-risk subjects aged >50 years is ongoing (predicted completion in 2017; NCT01887912).

Another vaccine, developed by Pfizer, is also formalin-inactivated but has mutations in Tcd A and TcdB to reduce toxigenicity.<sup>52</sup> A phase I placebo-controlled, randomised, observer-blinded study demonstrated efficacy with three parenteral doses.<sup>53</sup> Phase II randomised observer-blinded studies, due to complete shortly, are comparing this vaccine with placebo in 65-85 year olds (NCT02117570 and NCT02561195). The primary outcomes include TcdA and TcdB neutralising antibody responses and an assessment of vaccine-related adverse effects.

*C. difficile* toxins are difficult to purify and may degrade over time, making them challenging vaccine candidate antigens. For this reason, a vaccine (VLA84, Valneva) containing recombinant toxin domains is being developed, and has satisfactorily completed an open-label phase 1 study assessing safety, immunogenicity and dose response in healthy subjects. A press release in 2015 stated that a phase II trial of 500 US/German volunteers demonstrated safety and good immunogenicity, but further data are not yet available.<sup>54</sup> A phase 3 programme is being planned. Oral vaccination is another possibility, potentially using a vector such as *Bacillus subtilis* spores; CDVAX uses this method but is only at an early stage of development.<sup>55</sup>

### **Passive *C. difficile* protection - monoclonal antibodies**

Serum anti-toxin antibodies afford natural protection against recurrent CDI, but we do not understand what controls the production of these by some but not all individuals. There are no routinely available tests to measure anti-toxin antibodies (in either serum or faeces). Bezlotoxumab has been developed as a human monoclonal antibody that binds to and neutralizes *C. difficile* toxin B. It is given as a single infusion during standard of care CDI antibiotic therapy. In phase 3 clinical trials, bezlotoxumab was compared with actoxumab (a monoclonal antibody to toxin A), a combination of actoxumab and bezlotoxumab.<sup>56</sup> The primary endpoint was recurrent CDI, after initial clinical cure, within 12 weeks. Actoxumab was found to be ineffective at a planned interim analysis, and so was ceased. Bezlotoxumab had no effect on the initial clinical cure of CDI, but significantly reduced recurrence rates compared with placebo (17% vs. 27%, -10.0 95% CI -14.0,-6.0;  $p < 0.0003$ ); actoxumab plus bezlotoxumab did not confer additional protection against recurrence. The 40% relative reduction in CDI recurrence achieved by bezlotoxumab was maintained across 4 vs 8 vs 12 weeks of follow up. Also, recurrence rate were lower in pre-defined subgroups with high risk of recurrent CDI and/or adverse outcome, including patients aged  $\geq 65$  years, those with CDI in the past 6 months, severe CDI, and the immunocompromised. The safety profile of bezlotoxumab was similar to that of placebo. In-patients treated with bezlotoxumab compared with placebo had fewer CDI-associated hospital readmissions (4.0% vs 9.6%, difference -5.7% [95% CI: -8.8, -2.7]) and all-



cause readmissions (23.2% vs. 26.9%, difference -3.7% [95% CI: -9.0, 1.5]) in the 30-days after discharge, in a post-hoc analysis.<sup>57</sup> Notably, bezlotoxumab was also associated with significant reductions in CDI-associated hospital readmissions in inpatients aged  $\geq 65$  years, with a history of  $\geq 1$  CDI episode in the past 6 months, and cases with clinically severe CDI.

A FDA Antimicrobial Drugs Advisory Committee voted 10 to 5 (1 abstention) in June 2016 to recommend bezlotoxumab injection for the prevention of CDI recurrence (<http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM505290.pdf>). If approved for the prevention of recurrent CDI (decision expected in late 2016), bezlotoxumab would be the first therapeutic to attain this indication.

### **Microbiome based therapeutics**

Live biotherapeutics drugs (as opposed to foodstuffs) are regulated by the Food and Drug Administration (FDA) in a similar manner to drugs. An investigational new drug (IND) application is required, and the drug must be safe, pure, potent, and consistently produced according to good manufacturing practices.

#### *Faecal microbiota transplantation*

The evidence base concerning the effectiveness of FMT continues to grow, notably following the publication of the first randomised controlled trial in 2013.<sup>58</sup> FMT is still essentially an experimental, non-standardised procedure, but attracts considerable interest and support, not least due to unmet patient needs for effective therapies for multiple recurrences of CDI. The potential benefits and risks of FMT are summarised in Table 2. Organisations such as Openbiome aim to overcome some of the practical barriers to FMT, by facilitating access to screened faecal transplant material (<http://www.openbiome.org/impact/>).

Potential safety issues surrounding the administration of live faeces-derived mixtures of microorganisms, are a concern; such biotherapeutics may include species of unknown significance, which could be beneficial or harmful, including non-cultivable/unknown microbes. The longer term consequences of manipulation of the gut microbiota are unknown. Such issues underlie the restrictions that different regulatory authorities have imposed on the use of FMT, primarily to safeguard patient interests. These include in some settings the need for an IND, and requirements for consenting subjects, screening of donors and recipients. Furthermore, the need for faecal

material preparation and delivery via either rectal or nasogastro/duodenal routes mean that there are intensive endeavours to develop alternatives to FMT, which can reduce risk and/or simplify delivery, and yet still harness the beneficial properties of the gut microbiota

Recent studies have examined the use of freeze-thawed and encapsulated material for FMT.<sup>59,60</sup> Freeze-thawed versus fresh faeces delivered via an enema achieved rates of clinical resolution without recurrence up to 13 weeks compared with that were not significantly different in per-protocol (83.5% vs. 85.1%) and mITT (75.0% vs. 70.3%) populations.<sup>59</sup> However, about one third of the subjects in each treatment group, who were ultimately classified as resolved according to the study protocol, required two FMTs. It is a relatively common finding that repeat FMT administration is required to prevent recurrences.

A small non-blinded, non-randomised study of encapsulated (and freeze-thawed) faeces was carried out in 20 subjects with  $\geq 3$  episodes of mild-to-moderate CDI and failure of a 6-8-weeks of vancomycin therapy or  $\geq 2$  episodes of severe CDI requiring hospitalization.<sup>32</sup> Resolution of diarrhoea was achieved in 14 patients (70%; 95% CI, 47%-85%) after a single capsule-based FMT; 4/6 re-treated non-responders had resolution of diarrhea, resulting in an overall 90% (95% CI, 68%-98%) response rate. No serious adverse events were attributed to FMT.

#### *Live biotherapeutic microbiota preparations*

RBX2660 is a live biotherapeutic microbiota suspension that aims to harness the effectiveness of FMT, but within a standardised, regulated product, for the treatment of recurrent CDI. In the first of two phase 2 studies, 34 subjects (with  $\geq 2$  recurrent CDI episodes or  $\geq 2$  severe episodes resulting in hospitalization) received at  $\geq 1$  dose of RBX2660 and 31 completed 6 months follow up.<sup>61</sup> Following a 10-14 day course of CDI antibiotics and a 24-48 hour washout period, RBX2660 was administered as a single dose via enema. Further recurrent CDI occurred in 48% of subjects after one dose of RBX2660, with 15/31 patients receiving a second enema; of these, 78.6% were considered to be treatment successes, contributing to an overall success rate of 27/31 (87.1%). A second phase 2 study has recently been completed, but results are not yet available.

SER-109 (Seres) is also a live biotherapeutic that comprises an encapsulated mixture of purified *Firmicutes* spores, derived from human faeces. As the spores are resilient to manipulation, ethanol treatment has been used to theoretically reduce the risk of transmissible, harmful infectious agents contaminating the therapeutic product. Seres has completed two phase 2 studies of SER-109. The

first of these was a non-comparative study in patients with  $\geq 3$  CDI episodes in the previous 12 months.<sup>62</sup> 26/30 patients (86.7%) across two dosing groups met the primary efficacy end point (absence of *C. difficile*-positive diarrhoea during 8 weeks of follow-up). 96.7% of subjects were considered to have achieved clinical resolution, as 3 patients with early, self-limiting *C. difficile*-positive diarrhoea did not require antibiotic treatment. Notably, the loss of diversity of gut microbiota that is typical in CDI patients rapidly reversed after receipt of SER-109. The interim results of the second, recently completed, phase 2 (ECOSPORE) study of SER-109 have just been released (<http://ir.serestherapeutics.com/phoenix.zhtml?c=254006&p=irol-newsArticle&ID=2190006> ). SER-109 was not effective overall at reducing CDI recurrence, but was efficacious in subjects aged  $\geq 65$  years old, in whom CDI recurrence occurred in 14/31 (45%) of subjects who received SER-109 versus 12/15 (80%) of those who received placebo. Further analyses will be important to understand these results.

#### *Non-toxigenic C. difficile*

A randomized, double-blind, placebo-controlled, dose-ranging study examined the efficacy of a non-toxigenic *C difficile* (NTCD) strain to prevent recurrent *C difficile* infection (CDI), presumably by displacing (blocking) toxigenic bacteria remaining after CDI antibiotic treatment.<sup>63</sup> About two thirds (69%) of NTCD recipients were colonized, with only a 2% CDI recurrence rate in these patients. However, of those not colonized by NTCD, recurrence occurred in 31% (similar to placebo). Of note, none of the subjects who were colonized at week 6 remained colonized by week 26.

#### **Summary**

There are a number of promising approaches aimed at tackling the global challenge of CDI. However, further trials are required to determine which, if any, can take a role in the routine primary prevention, treatment and/or secondary prevention of CDI.

#### **Key points (3-5)**

1. *C. difficile* remains a significant cause of morbidity and mortality worldwide. Current approaches to reduce CDI using antimicrobial stewardship and infection prevention programmes have not led to a consistent marked decline in disease rates.
2. Historically, two antibiotics (metronidazole and vancomycin) and a recent third (fidaxomicin) have been used routinely for CDI treatment; convincing data are now available showing that metronidazole is the least efficacious agent.

3. Novel antimicrobial agents are being evaluated in Phase III trials; it is not yet clear what will be the roles of these agents in future CDI treatment.
4. Prophylaxis is an optimum approach to reduce the impact of CDI especially in high-risk populations; monoclonal antibodies, antibiotic blocking approaches and multiple vaccines are currently in advanced clinical trials.
5. The treatment of recurrent CDI is particularly troublesome, and several different live biotherapeutics are being developed, in addition to faecal microbiota transplantation (FMT).

### **Acknowledgements**

None.

### **Financial support and sponsorship**

None.

### **Conflicts of Interest**

MHW has received: consulting fees from Actelion, Astellas, bioMerieux, MedImmune, Merck, Pfizer, Qiagen, Sanofi-Pasteur, Seres, Summit, Synthetic Biologics and Valneva; lecture fees from Alere, Astellas, Merck & Pfizer; and grant support from Actelion, Astellas, bioMerieux, Da Volterra, Merck, Sanofi-Pasteur, Seres and Summit. JM has received speaker fees from Pfizer.

### **References**

1. CDC. 2013 Annual Report for the Emerging Infections Program for Clostridium difficile Infection. <https://www.cdc.gov/hai/eip/pdf/2013-Annual-Report-12-8-2015.pdf>
2. Public Health England. Annual Epidemiological Commentary. Mandatory MRSA, MSSA and *E. coli* bacteraemia and *C. difficile* infection data 2015/16. <https://www.gov.uk/government/statistics/mrsa-mssa-and-e-coli-bacteraemia-and-c-difficile-infection-annual-epidemiological-commentary>
3. Knetsch CW, Connor TR, Mutreja A, et al. Whole genome sequencing reveals potential spread of Clostridium difficile between humans and farm animals in the Netherlands, 2002 to 2011. *Euro surveillance*. 2014;19(45):20954.
4. Thitaram SN, Frank JF, Siragusa GR, et al. Antimicrobial susceptibility of Clostridium difficile isolated from food animals on farms. *International journal of food microbiology*. 2016 Jun 16;227:1-5.
5. Knight DR, Squire MM, Riley TV. Nationwide surveillance study of Clostridium difficile in Australian neonatal pigs shows high prevalence and heterogeneity of PCR ribotypes. *Applied and environmental microbiology*. 2015 Jan 1;81(1):119-23.
6. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America

- (SHEA) and the infectious diseases society of America (IDSA). *Infection Control & Hospital Epidemiology*. 2010 May 1;31(05):431-55.
7. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of *Clostridium difficile* infections. *The American journal of gastroenterology*. 2013 Apr 1;108(4):478-98.
  8. Van Nood E, Dijkgraaf MG, Keller JJ. Duodenal infusion of feces for recurrent *Clostridium difficile*. *N Engl J Med*. 2013 May 30;368(22):2145.
  9. Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent *Clostridium difficile* infection. *Alimentary pharmacology & therapeutics*. 2015 May 1;41(9):835-43
  10. Chang JY, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, Schmidt TM, Young VB. Decreased diversity of the fecal microbiome in recurrent *Clostridium difficile*—associated diarrhea. *Journal of Infectious Diseases*. 2008 Feb 1;197(3):435-8.
  11. Solomon K, Martin AJ, O'Donoghue C, et al. Mortality in patients with *Clostridium difficile* infection correlates with host pro-inflammatory and humoral immune responses. *Journal of medical microbiology*. 2013 Sep 1;62(9):1453-60.
  12. Soriano MM, Johnson S. Treatment of *Clostridium difficile* infections. *Infectious disease clinics of North America*. 2015 Mar 31;29(1):93-108.
  13. Johnson S, Louie TJ, Gerding DN, et al. Polymer Alternative for CDI Treatment (PACT) investigators. Vancomycin, metronidazole, or tolevamer for *Clostridium difficile* infection: results from two multinational, randomized, controlled trials. *Clinical Infectious Diseases*. 2014 Aug 1;59(3):345-54.
  14. Venugopal AA, Johnson S. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of *Clostridium difficile* infection. *Clinical infectious diseases*. 2011 Dec 7;cir830.
  15. Tannock GW, Munro K, Taylor C, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of *Clostridium difficile*-infected patients than does vancomycin. *Microbiology*. 2010 Nov 1;156(11):3354-9.
  16. Shue YK, Sears PS, Shangle S, Walsh RB, Lee C, Gorbach SL, Okumu F, Preston RA. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. *Antimicrobial agents and chemotherapy*. 2008 Apr 1;52(4):1391-5.
  17. Chilton CH, Crowther GS, Freeman J et al. Successful treatment of simulated *Clostridium difficile* infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure. *Journal of Antimicrobial Chemotherapy*. 2013 Sep 3:dkt347.
  18. Cornely OA, Crook DW, Esposito R, et al. OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with *Clostridium difficile* in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. *The Lancet infectious diseases*. 2012 Apr 30;12(4):281-9.
  19. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for *Clostridium difficile* infection. *New England Journal of Medicine*. 2011 Feb 3;364(5):422-31.
  20. Nathwani D, Cornely OA, Van Engen AK, Odufowora-Sita O, Retsa P, Odeyemi IA. Cost-effectiveness analysis of fidaxomicin versus vancomycin in *Clostridium difficile* infection. *J Antimicrob Chemother* 2014; 69: 2901-12.
  21. \*Goldenberg SD, Brown S, Edwards L, Gnanarajah D, Howard P, Jenkins D, Nayar D, Pasztor M, Oliver S, Planche T, Sandoe J, Wade P, Whitney L. The impact of the introduction of fidaxomicin on the management of *Clostridium difficile* infection in seven NHS secondary care hospitals in England: a series of local service evaluations. *Eur J Clin Microbiol Infect Dis* 2016;35:251-9.

*Real life experience, using a before and after design, of using fidaxomicin either for all or selected CDI cases; evidence of reduced incidence of recurrent CDI and possibly mortality, associated with use of fidaxomicin.*

22. Mascio CT, Mortin LI, Howland KT et al. In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of *Clostridium difficile*. *Antimicrobial agents and chemotherapy*. 2012 Oct 1;56(10):5023-30.
23. Alam MZ, Wu X, Mascio C, et al. Mode of action and bactericidal properties of surotomycin against growing and nongrowing *Clostridium difficile*. *Antimicrobial agents and chemotherapy*. 2015 Sep 1;59(9):5165-70.
24. Bouillaut L, McBride S, Sorg JA, et al. Effects of surotomycin on *Clostridium difficile* viability and toxin production in vitro. *Antimicrobial agents and chemotherapy*. 2015 Jul 1;59(7):4199-205.
25. Reigadas E, Alcalá L, Marín M, et al. In vitro activity of surotomycin against contemporary clinical isolates of toxigenic *Clostridium difficile* strains obtained in Spain. *Journal of Antimicrobial Chemotherapy*. 2015 Apr 15:dkv092.
26. Cannon K, Byrne B, Happe J, et al. Enteric microbiome profiles during a phase 2 clinical trial of CB-183,315 or vancomycin for treatment of *Clostridium difficile* infection. Abstract P2250 presented at the European Congress of Clinical Microbiology and Infectious Disease, London, United Kingdom. 2012.
27. Chesnel L, Sambol S, Gerding D, Patino H, Thorne G, Silverman J. Treatment of CDAD with oral CB-183 315: time to recurrence, relapse and re-infection rates compared with vancomycin. *Clin Microbiol Infect*. 2012;18(Suppl 3):380.
28. Boix V, Pesant Y, Fedorak RN, Mullane KM, Stoutenburgh U, Jin M, Guris D, Chesnel L, Murata Y. Primary clinical outcomes from a phase 3, randomized, double-blind, active-controlled study of surotomycin in patients with *Clostridium difficile*-associated diarrhea. European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, 2016. Abstract P0612.
29. Gehin M, Desnica B, Dingemans J. Minimal systemic and high faecal exposure to cadazolid in patients with severe *Clostridium difficile* infection. *International journal of antimicrobial agents*. 2015 Nov 30;46(5):576-81.
30. Chilton CH, Crowther GS, Baines SD, et al. In vitro activity of cadazolid against clinically relevant *Clostridium difficile* isolates and in an in vitro gut model of *C. difficile* infection. *Journal of Antimicrobial Chemotherapy*. 2013 Oct 14:dkv411.
31. Baldoni D, Gutierrez M, Timmer W, Dingemans J. Cadazolid, a novel antibiotic with potent activity against *Clostridium difficile*: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses. *Journal of Antimicrobial Chemotherapy*. 2014 Mar 1;69(3):706-14.
32. Louie T, Nord CE, Talbot GH, et al. Multicenter, double-blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with *Clostridium difficile* infection. *Antimicrobial Agents and Chemotherapy*. 2015 Oct 1;59(10):6266-73.  
*Phase 2 clinical trial data for a novel hybrid antibiotic, cadazolid, showing non-inferiority at treating CDI in comparison with vancomycin.*
33. Goldstein EJ, Citron DM, Tyrrell KL, et al. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against *Clostridium difficile* and 350 Gram-positive and Gram-negative aerobic and anaerobic intestinal flora isolates. *Antimicrobial Agents and Chemotherapy*. 2013 Oct 1;57(10):4872-6.

34. Corbett D, Wise A, Payne LJ, et al. SMT19969: In vitro pharmacodynamics against *Clostridium difficile*. In: Twenty-third European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany 2013.
35. Sattar A, Thommes P, Payne L, et al. SMT19969 for *Clostridium difficile* infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI. *Journal of Antimicrobial Chemotherapy*. 2015 Jun 1;70(6):1757-62.
36. Weiss W, Pulse M, Vickers R. In vivo assessment of SMT19969 in a hamster model of *Clostridium difficile* infection. *Antimicrobial agents and chemotherapy*. 2014 Oct 1;58(10):5714-8.
37. Baines SD, Crowther GS, Freeman J, et al. SMT19969 as a treatment for *Clostridium difficile* infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model. *Journal of Antimicrobial Chemotherapy*. 2015 Jan 1;70(1):182-9.
38. Vickers R, Robinson N, Best E, et al. A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for *Clostridium difficile* infections. *BMC infectious diseases*. 2015 Feb 25;15(1):1.
39. \*\*Vickers RJ, Tillotson GS, Nathan R, et al. Ridinilazole for *Clostridium difficile* infections: safety and efficacy compared with vancomycin from the CoDIFY phase 2 trial. *European Congress Clinical Microbiology and Infectious Disease, Amsterdam, Netherlands, 2016. Abstract EP0177.*  
*Abstract results of a phase 2 clinical trial demonstrating superiority of a novel oral antibiotic, ridinilazole (SMT19969), in comparison with vancomycin in achieving a sustained clinical response, which was driven by a reduced rate of recurrent CDI.*
40. Kaleko M, Bristol JA, Hubert S, et al. Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent *Clostridium difficile* infection. *Anaerobe*. 2016 Jun 2.
41. \*Connelly S, Widmer G, Mukherjee J, et al. SYN-004, a Clinical Stage Oral Beta-Lactamase Therapy, Protects the Intestinal Microflora from Antibiotic-Mediated Damage in Humanized Pigs. *Gastroenterology* 2015 148, (4) S1195-S1195.  
*Animal model data showing that an orally administered  $\beta$ -lactamase can prevent the deleterious effects of  $\beta$ -lactam antibiotics on gut microbiota (and so theoretically CDI).*
42. Roberts T, Kokai-Kun JF, Coughlin O, et al. Tolerability and Pharmacokinetics of SYN-004, an Orally Administered  $\beta$ -Lactamase for the Prevention of *Clostridium difficile*-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies. *Clinical Drug Investigation*. 2016 Jun 9:1-0.
43. \*de Gunzburg J, Ducher A, Modess C, et al. Targeted adsorption of molecules in the colon with the novel adsorbent-based Medicinal Product, DAV132: A proof of concept study in healthy subjects. *The Journal of Clinical Pharmacology*. 2015 Jan 1;55(1):10-6.  
*Early proof of concept data for a novel charcoal based absorbent to prevent the deleterious effects of antibiotics on gut microbiota (and so theoretically CDI).*
44. Lee BY, Popovich MJ, Tian Y, et al. The potential value of *Clostridium difficile* vaccine: an economic computer simulation model. *Vaccine*. 2010 Jul 19;28(32):5245-53.
45. Kyne L, Warny M, Qamar A, et al. Asymptomatic carriage of *Clostridium difficile* and serum levels of IgG antibody against toxin A. *New England Journal of Medicine*. 2000 Feb 10;342(6):390-7.

46. Kyne L, Warny M, Qamar A, et al. Association between antibody response to toxin A and protection against recurrent *Clostridium difficile* diarrhoea. *The Lancet*. 2001 Jan 20;357(9251):189-93.
47. Kuehne SA, Cartman ST, Heap JT, et al. The role of toxin A and toxin B in *Clostridium difficile* infection. *Nature*. 2010 Oct 7;467(7316):711-3.
48. Péchiné S, Gleizes A, Janoir C, et al. Immunological properties of surface proteins of *Clostridium difficile*. *Journal of medical microbiology*. 2005 Feb 1;54(2):193-6.
49. Foglia G, Shah S, Luxemburger C, et al. *Clostridium difficile*: development of a novel candidate vaccine. *Vaccine*. 2012 Jun 19;30(29):4307-9.
50. Kotloff KL, Wasserman SS, Losonsky GA, et al. Safety and Immunogenicity of Increasing Doses of a *Clostridium difficile* Toxoid Vaccine Administered to Healthy Adults. *Infection and immunity*. 2001 Feb 1;69(2):988-95.
51. \*de Bruyn G, Saleh J, Workman D, Pollak R, Elinoff V, Fraser NJ, Lefebvre G, Martens M, Mills RE, Nathan R, Trevino M. Defining the optimal formulation and schedule of a candidate toxoid vaccine against *Clostridium difficile* infection: A randomized Phase 2 clinical trial. *Vaccine*. 2016 Apr 27;34(19):2170-8.  
*Phase 2 clinical trial that established the optimum dose and requirement for adjuvant of current lead C. difficile vaccine.*
52. Donald RG, Flint M, Kalyan N, et al. A novel approach to generate a recombinant toxoid vaccine against *Clostridium difficile*. *Microbiology*. 2013 Jul 1;159(7):1254-66.
53. \*Sheldon E, Kitchin N, Peng Y, Eiden J, Gruber W, Johnson E, Jansen KU, Pride MW, Pedneault L. A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a *Clostridium difficile* vaccine administered with or without aluminum hydroxide in healthy adults. *Vaccine*. 2016 Apr 19;34(18):2082-91.  
*Early proof of concept data for novel C. difficile vaccine.*
54. Valneva Se, France. Press release November 2015. <http://www.valneva.com/en/rd/vla84>
55. Permpoonpattana P, Hong HA, Phetcharaburanin J, et al. Immunization with *Bacillus* spores expressing toxin A peptide repeats protects against infection with *Clostridium difficile* strains producing toxins A and B. *Infection and immunity*. 2011 Jun 1;79(6):2295-302.
56. \*\*Wilcox, M. et al. Bezlotoxumab alone and with actoxumab for prevention of recurrent *C. difficile* infection in patients on standard of care antibiotics: integrated results of 2 Phase 3 studies (MODIFY I and MODIFY II). *Open Forum Infect. Dis.* [online], [http://ofid.oxfordjournals.org/content/2/suppl\\_1/67.short](http://ofid.oxfordjournals.org/content/2/suppl_1/67.short) (2015).  
*Abstract data from phase 3 clinical trials of bezlotoxumab, a monoclonal antibody against C. difficile toxin B, showing approximately 40% relative reduction in recurrent CDI when given with standard of care antibiotics.*
57. \*Golan Y, Dubberke E, Hanson M, Liao J, Pedley A, Dorr M, Marcella S, Prabhu V. Bezlotoxumab (BZO) decreases recurrence and is associated with a reduction in 30-day *Clostridium difficile* infection-associated readmissions in hospitalized patients with CDI. *ASM Microbe*, June 16-20, 2016, Boston. Abstract 449.  
*Pharmacoeconomic data from phase 3 studies of bezlotoxumab demonstrating potential beneficial effects of reduced CDI recurrence in terms of lower readmission rates.*
58. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. Duodenal infusion of donor feces for recurrent *Clostridium difficile*. *N Engl J Med* 2013;368:407-15.
59. \*\*Lee CH, Steiner T, Petrof EO, Smieja M, Roscoe D, Nematallah A, Weese JS, Collins S, Moayyedi P, Crowther M, Ropeleski MJ, Jayaratne P, Higgins D, Li Y, Rau NV, Kim PT. Frozen



vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. JAMA 2016;315:142-9.

*Clinical trial demonstrating that freeze-thawed faeces delivered via an enema was as effective as versus fresh faeces at preventing recurrences of CDI. Approximately one third of subjects required two FMTs to achieve resolution.*

60. Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 2014;312:1772-8.

61. \*\*Orenstein R, Dubberke E, Hardi R, Ray A, Mullane K, Pardi DS, Ramesh MS; PUNCH CD Investigators. Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study. Clin Infect Dis 2016;62:596-602.

*Phase 2 clinical trial showing that a mixture of gut bacteria can prevent CDI recurrences.*

62. \*\*Khanna S, Pardi DS, Kelly CR, Kraft CS, Dhere T, Henn MR, Lombardo MJ, Vulic M, Ohsumi T, Winkler J, Pindar C, McGovern BH, Pomerantz RJ, Aunins JG, Cook DN, Hohmann EL. A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection. J Infect Dis 2016;214:173-81.

*Phase 2 clinical trial providing proof of principle that a mixture of bacterial spores can prevent further recurrences in patients with recurrent CDI.*

63. \*\*Gerding DN, Meyer T, Lee C, Cohen SH, Murthy UK, Poirier A, Van Schooneveld TC, Pardi DS, Ramos A, Barron MA, Chen H, Villano S. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA 2015;313:1719-27.

*Phase 2 clinical trial demonstrating the efficacy of a new concept to prevent CDI recurrences using a non-toxigenic C. difficile strain.*